POEMS syndrome presentation with progressive weakness in upper and lower limbs: A case report

CHUANG-JIE CAO¹*, CHENG-YUN DOU²*, KE-HUA ZHOU³, JIN-BO LIU³ and HONG LAI³

¹Department of Pathology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080; Departments of ²Hepatology and ³Endocrinology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China

Received July 6, 2016; Accepted May 11, 2017

DOI: 10.3892/ol.2017.6904

Abstract. Polyneuropathy, organomegaly, endocrinopathy, M proteins, and skin changes (POEMS) syndrome is a rare variant of plasma cell disorders with multiple systemic manifestations. A 50-year-old female patient presented with progressive weakness in her upper and lower limbs; tingling, numbness and burning in her feet; polyneuropathy (demyelinating in the majority of cases of POEMS syndrome); monoclonal plasma cell disorder (typically λ-restricted in cases of POEMS syndrome); sclerotic lesions on the spine and pelvis; organomegaly, including hepatomegaly, splenomegaly and lymphadenopathy; edema; pleural effusion; adrenal, thyroidal, pituitary, gonadal and pancreatic endocrinopathy; skin changes, including hyperpigmentation, dry skin and hypertrichosis; thrombocytosis; pulmonary hypertension; low vitamin B12 and weight loss. Following the diagnosis of POEMS syndrome, the patient was treated only with pain-alleviating corticosteroids. Respiratory failure-induced mortality occurred 24 months after the patient first experienced difficulty walking and numbness in her lower extremities. The present study suggests that abnormal symptoms in cases of POEMS syndrome should be further evaluated during the diagnosis and treatment.

Introduction

Diagnosing polyneuropathy, organomegaly, endocrinopathy, and M protein and skin changes (POEMS) syndrome does not require the patient to present all symptoms in the aforementioned acronym (1). Furthermore, the POEMS acronym does not include all POEMS syndrome-associated symptoms, and there is a Castleman disease variant of POEMS syndrome that may be associated with clonal plasma cell disorder (2). POEMS syndrome is a rare paraneoplastic syndrome associated with an underlying plasma cell disorder (2). Cases of POEMS syndrome have been reported in Japan (3-5), France, the United States, China and India (6-9). However, the incidence and prevalence of POEMS syndrome is unknown (10). Though the mechanism by which plasma cells cause POEMS syndrome remains to be fully understood, increased levels of vascular endothelial growth factor (VEGF) may be a factor (11).

POEMS syndrome is potentially fatal and is associated with a substantial deterioration in quality of life through neuropathy, anasarca, thromboembolic events and cachexia (12,13). Early diagnosis and a multidisciplinary approach may increase the likelihood of reducing long-term irreversible morbidity.

Weakness in the upper and lower limbs is a common symptom of multiple diseases, including neuromuscular disorders (14), amyotrophic lateral sclerosis (15), multiple sclerosis, Guillain-Barre syndrome, transverse myelitis (16), hypervitaminosis D (17) and POEMS syndrome. Hence, presentation with weakness in the upper and lower limbs in patients with POEMS syndrome may not result in the correct diagnosis. The patient with POEMS syndrome described in the present study initially presented with weakness in the upper and lower limbs 2 years ago, and subsequently succumbed to respiratory failure at age 50 due to delayed diagnosis of POEMS syndrome. The present study intends to improve the understanding of POEMS syndrome among healthcare professionals.

Case report

On 3 March 2014, a 50-year-old female patient was admitted to the Department of Endocrinology, Qilu Hospital of Shandong University (Jinan, China), complaining of progressive weakness in her upper and lower limbs, which frequently failed. Furthermore, the patient was experiencing tingling, numbness and burning in her feet. The patient had a 3-year history of diffuse hyperpigmentation and slight anasarca, and a 2-month history of lumbodynia and debilitation, pain and numbness all over her body. In addition, the patient was diagnosed with
type 2 diabetes at the Affiliated Hospital of Binzhou Medical School (Binzhou, China). Written informed consent was obtained from the patient for the publication of the present case report and any accompanying images.

On admission, a physical examination revealed chronic facies (pale or grey look caused by chronic disease) and unstable vital signs. Measurements were taken, including body temperature, 36.0°C (normal range, 36-37°C); respiration rate, 19 breaths/min (normal range, 16-20 breaths/min); heart rate, 78 beats/min (normal range, 60-100 beats/min); and blood pressure, 197/107 mmHg (normal range, ±120/80 mmHg). Physical examination revealed diffuse hyperpigmentation, which was particularly severe on the upper trunk and limbs; dry skin; hypertrichosis (Fig. 1A); and leukonychia. The patient exhibited continued mild edema in her facial tissues and lower limbs (Fig. 1B). Palpable, soft rubbing lymph nodes were revealed in the axillary fossa. The patient exhibited splenomegaly and amenorrhea. Bilateral rales were heard with a stethoscope on auscultation. The body mass of the patient had decreased by ~10 kg in the past year.

The blood cell count demonstrated an increase of platelets (4.56x10^11 cells/l), and a decrease in albumin (29.3 g/l) and albumin/globulin ratio (0.88:1). However, electrolytes, liver and renal function were within normal limits. Analysis of blood coagulation serials revealed increased prothrombin time, increased standardization of prothrombin time ratio, decreased prothrombin time activity, activated partial thromboplastin time, increased plasma D‑Dimer. These results revealed that the patient exhibited coagulation disorders. The results of endocrine hormone analysis revealed decreased free triiodothyronine, tetraiodothyronine and thyroglobulin, and increased thyroid-stimulating hormone, consistent with the symptoms of hypothyroidism. Symptoms of endocrinopathy included thyroidal, pituitary, gonadal and pancreatic endocrinopathy; organomegaly, including hepatomegaly, splenomegaly and lymphadenopathy; edema; pleural effusion; adenral, thyroidal, pituitary, gonadal and pancreatic endocrinopathy; skin alterations, including hyperpigmentation, dry skin and hypertrichosis; thrombocytosis; pulmonary hypertension; low vitamin B12 values; and weight loss supported the diagnosis of POEMS syndrome.

POEMS syndrome was diagnosed using a combination of history and examination results according to the 2014 update on diagnosis, risk-stratification and management of POEMS syndrome (18). The presence of polyneuropathy (demyelinating in the majority of cases of POEMS syndrome); monoclonal plasma cell disorder (typically λ-restricted in cases of POEMS syndrome); sclerotic lesions on the spine and pelvis; organomegaly, including hepatomegaly, splenomegaly and lymphadenopathy; edema; pleural effusion; adrenal, thyroidal, pituitary, gonadal and pancreatic endocrinopathy; skin alterations, including hyperpigmentation, dry skin and hypertrichosis; thrombocytosis; pulmonary hypertension; low vitamin B12 values; and weight loss supported the diagnosis of POEMS syndrome.

Subsequently, the patient received a low-dose steroid treatment (oral prednisolone 10 mg/day). However, when the patient refused further positive medication, conservative treatment was used to alleviate the pain and relieve symptoms. Respiratory failure induced mortality in the patient 9 days following admission to the hospital; the patient was aged 50.

**Discussion**

In 1980, Bardwick et al reported POEMS syndrome for the first time (19). Subsequently POEMS syndrome has been diagnosed based on a composite of clinical and laboratory features (12), and is misdiagnosed in patients that present with it if the syndrome is not considered. The pathogenesis of the syndrome remains to be fully understood. Overproduction of proinflammatory cytokines, including interleukin (IL)-1β, IL-6, tumor necrosis factor-α, and VEGF, have been reported...
Table I. Laboratory test results of the initial assessment of the patient.

A, Blood cells

| Type of blood cell               | Value  | Change relative to normal value | Normal value |
|----------------------------------|--------|---------------------------------|--------------|
| Red blood cells, x10⁹ cells/l    | 5.24   |                                 | 3.50-5.50    |
| White blood cells, x10⁹ cells/l  | 5.80   |                                 | 4.00-10.00   |
| Neutrophils, x10⁹ cells/l        | 2.80   | ↓                               | 3.00-5.00    |
| Lymphocytes, x10⁹ cells/l        | 2.30   |                                 | 1.00-3.00    |
| Monocytes, x10⁹ cells/l          | 0.50   |                                 | 0.07-0.33    |
| Eosinophils, x10⁹ cells/l        | 0.10   |                                 | 0.05-0.50    |
| Basophils, x10⁹ cells/l          | 0.00   | ↓                               | 0.02-0.05    |
| Platelets, x10⁹ cells/l          | 456.00 | ↑                               | 100.00-300.00|
| ESR, mm/h                        | 13.00  |                                 | 0.00-20.00   |

B, Proteins

| Type of protein                  | Concentration | Change relative to normal concentration | Normal concentration |
|----------------------------------|---------------|-----------------------------------------|----------------------|
| Albumin, g/l                     | 29.30         | ↓                                       | 40.00-55.00          |
| Globulin, g/l                    | 33.20         |                                         | 0.00-40.00           |
| Albumin/globulin                 | 0.88:1        | ↓                                       | 1.20-2.40            |
| Ig G, g/l                        | 15.00         |                                         | 7.00-16.00           |
| Ig A, g/l                        | 5.43          | ↑                                       | 0.70-4.00            |
| Ig M, g/l                        | 0.88          |                                         | 0.40-2.30            |
| Ig E, g/l                        | 51.50         |                                         | 0.00-100.00          |
| C3, g/l                          | 0.56          | ↓                                       | 0.90-1.80            |
| C4, g/l                          | 0.16          |                                         | 0.10-0.40            |
| κ light chain, g/l               | 4.18          | ↑                                       | 1.70-3.70            |
| λ light chain, g/l               | 2.58          | ↑                                       | 0.90-2.10            |
| κ/λ                              | 1.62:1        |                                         | 1.35-2.65            |

C, Coagulation serials

|                                | Value    | Change relative to normal value | Normal value |
|--------------------------------|----------|---------------------------------|--------------|
| Prothrombin time, sec          | 21.10    | ↑                               | 11.00-14.50  |
| INR                            | 1.90     | ↑                               | 0.80-1.20    |
| Prothrombin time activity, %    | 41.00    | ↓                               | 70.00-120.00 |
| APTT, sec                       | 86.30    | ↑                               | 28.00-45.00  |
| Fibrinogen, g/l                | 2.11     |                                 | 2.00-4.00    |
| Plasma D-Dimer, µg              | 3.77     | ↑                               | 0.00-0.50    |

D, Hormone

| Type of hormone                 | Value    | Change relative to normal value | Normal value |
|---------------------------------|----------|---------------------------------|--------------|
| Free triiodothyronine, pmol/l   | 2.21     | ↓                               | 2.30-6.30    |
| Free tetraiodothyronine, pmol/l | 6.28     | ↓                               | 10.30-24.50  |
| Thyroid-stimulating hormone, UIU/ml | 6.19 | ↑                               | 0.35-5.50    |
| Thyroglobulin, ng/ml            | 0.32     | ↓                               | 1.40-7.80    |
| Prolactin, ng/ml                | 48.26    | ↑                               | 3.40-24.10   |
| Testosterone, ng/ml             | <0.03    | ↓                               | 0.06-0.82    |
| ACTH, pg/ml; 00:00              | 21.63    | ↑                               | 0.00-10.00   |
| ACTH, pg/ml; 08:00              | 139.70   | ↑                               | 4.70-48.80   |
| ACTH, pg/ml; 16:00              | 14.57    | ↑                               | 0.00-46.00   |
| Vitamin B₁₂, pg/ml              | 145.30   | ↓                               | 190.00-940.00|

ESR, erythrocyte sedimentation rate; Ig, immunoglobulin; C, complement; INR, international normalized ratio; APTT, activated partial thromboplastin time; ACTH, adrenocorticotropic hormone.
and may serve important etiological functions (20-22). Of these proinflammatory cytokines, only increased VEGF serves as a major criterion for the diagnosis of POEMS syndrome (12). VEGF potentially causes effusions, pulmonary hypertension and disseminated intravascular coagulation (23,24), and is associated with POEMS syndrome activity (25).

The diagnosis of POEMS syndrome depends on a thorough history and a full examination of systems. The majority of authors agree that the presence of two major and at least one minor criteria are confirmatory (25). The mandatory major criteria for POEMS syndrome is polyradiculoneuropathy (typically demyelinating) and monoclonal plasma cell disorder. The patient described by the present study exhibited lumbodynia, pain and numbness all over the body, and the EMG test revealed extensive motor and sensory polyneuropathy, with typical demyelination at the proximal and distal
ends of peripheral nerves in all four limbs. Serum-protein electrophoresis detected high levels of IgG, \( \lambda \) and \( \kappa \) light chains; serum immunofixation demonstrated that IgG, \( \kappa \) and L were positive, and that IgA and IgM were negative, which matched with the results demonstrated by Dispenzieri et al (1). However, analysis of the bone marrow of the patient revealed no osteolytic lesions or plasma cell myeloma. MRI demonstrated a degenerative lumbar spine, L3/4 and L5/S1 diskal hernia and sclerotic bone lesion-associated osteosclerotic nodules on spine and pelvis. VEGF is associated with POEMS syndrome activity (24). However, since our hospital (Qilu Hospital of Shandong University) was not able to detect serum VEGF level, the present study did not determine the VEGF levels of the patient. In addition, organomegaly in POEMS syndrome typically occurs in the liver, spleen, and lymph nodes. The patient in the present study presented with splenomegaly and lymphadenopathy of bilateral axilla. Extravascular volume overload, including edema; pleural, abdominal cavity and pericardial effusion and ascites supported a diagnosis of POEMS syndrome. The presence of autoantibodies against the thyroid gland, type 2 diabetes, increased PRL and ACTH, decreasing TEST, and an empty sella turcica were considered to be evidence of endocrinopathy. Hyperpigmentation was the most common abnormality of skin alterations. A routine blood test identified thrombocytosis. Weight loss, pulmonary hypertension, thrombotic diatheses and low vitamin B\(_{12}\) levels also aided in the diagnosis of POEMS syndrome.

Currently, treatments for POEMS syndrome include radiation, chemotherapy, bone marrow transplantation and the use of other drugs, including alkylators, corticosteroids, bevacerucizumab, rituximab, bortezomib, and thalidomide (26,27). Surgical resection maybe a potential treatment in the event of infection-associated complications, or the presence of a solitary tumor (28). Although an anti-VEGF strategy appears to be effective, limitations have been reported (29). Due to financial limitations and the severity of her condition, the patient in the

![Figure 3. Representative CT images. (A) Arrows denote bilateral ascites. (B) Arrows denote bilateral pleural and pericardial effusion. (C) Pulmonary arterial hypertension (the diameter ratio of the pulmonary artery with aorta was ≥1; the diameters of the pulmonary artery and the aorta were 39.9 and 34.5 mm, respectively. (D) CT scan of the thorax revealed mixed ground-glass opacity and minimal consolidation, and intralobular reticulations and septal thickening, suggesting the presence of pulmonary edema. CT, computed tomography.](image1)

![Figure 4. Serum protein electrophoresis with immunofixation revealed IgG, \( \kappa \) and L were positive, and that IgA and IgM were negative. L, K, M, A, G and ELP represent \( \lambda \) light chain, \( \kappa \) light chain, IgM, IgA, IgG and reference light protein, respectively. Ig, immunoglobulin; ELP, elastin-like polypeptide.](image2)
present study refused any further positive therapy, using only pain-alleviating corticosteroids.

POEMS syndrome exhibits a chronic clinical course. Follow-up data revealed that the median survival time of patients is 165 months from the Mayo Clinic dysproteinemia database (1). A Chinese survey revealed that, 25 months on from the initial diagnosis, 80% of patients were alive after 25 months and 10% of these patients survived >60 months (8). Cardiorespiratory failure, along with pneumonia, was the most common means by which mortality occurred (1). Respiratory failure induced mortality in the patient described by the present study 24 months following the initial onset of difficulty walking and numbness in the lower limbs. The patient was aged 50.

POEMS syndrome is a rare paraneoplastic disorder consisting of peripheral neuropathy, organomegaly, endocrinopathy, and M protein and skin changes. The present study described a novel case of POEMS syndrome associated with the inconstant symptom of progressive weakness in the upper and lower limbs. The patient first entered hospital with the same symptom 2 years prior to her diagnosis. However, these symptoms were not identified as those of POEMS syndrome. Therefore, the present study recommends that more care reports concerning abnormal symptom-associated POEMS syndrome should be considered to improve the future diagnosis and treatment of POEMS syndrome, and enhance understanding of the syndrome.

References

1. Dispensieri A, Kyle RA, Lacy MQ, Rajkumar SV, Theraeu TM, Larson DR, Greipp PR, Witzig TE, Basu R, Suarez GA, et al: POEMS syndrome: Definitions and long-term outcome. Blood 101: 2496-2506, 2003.
2. Dispensieri A: POEMS syndrome: 2011 update on diagnosis, risk-stratification and management. Am J Hematol 86: 592-601, 2011.
3. Sanada S, Ooakawa S, Karube H, Shinjo T, Goto T, Nakamichi T, Saito M, Matsubara M and Suzuki M: Marked recovery of severe renal lesions in POEMS syndrome with high-dose melphalan therapy supported by autologous blood stem cell transplantation. Am J Kidney Dis 47: 672-679, 2006.
4. Nakamoto Y, Imai H, Yasuda T, Wakui H and Miura AB: A spectrum of clinicopathological features of nephropathy associated with POEMS syndrome. Nephrol Dial Transplant 14: 2370-2378, 1999.
5. Watanabe O, Arimura K, Kitajima I, Osame M and Maruyama I: Successful treatment with rituximab and thalidomide of POEMS syndrome associated with Waldenstrom macroglobulinemia. J Neurol Sci 297: 101-104, 2012.
6. Ohwada C, Nakaseko C, Sakai S, Takeda Y, Abe D, Takeuchi M, Sakaida E, Masuda S, Shimizu N, Cho R, et al: Successful combination treatment with bevacizumab, thalidomide and autologous PBSC for severe POEMS syndrome.Bone Marrow Transplant 43: 739-740, 2009.
7. Kotani Y, Ito M, Abumi K, Yasu K and Minami A: Neurological recovery from pentaplegia after resection for sacral plasmacytoma presenting with POEMS syndrome. J Neurosurg Spine 10: 324-328, 2009.
8. Allam JS, Kennedy CC, Aksamit TR and Dispensieri A: Pulmonary manifestations in patients with POEMS syndrome: A retrospective review of 137 patients. Chest 133: 969-974, 2008.